Biocon Biologics has secured marketing approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar.
The product is a biosimilar to Amgen's blockbuster drug Neulasta, developed to treat chemotherapy-induced neutropenia.
Sandoz K.K. will exclusively promote, sell, and distribute the drug in Japan, expanding Biocon's market footprint in highly regulated advanced economies.
More on Stocks
Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.
Market sentiment intelligence for apps, funds & agents
Location
729 55 Ave SW
Calgary AB T2V 0G4
Canada
© 2026 Guavy Inc
